These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12735973)

  • 1. 90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer.
    Yu J; Häfeli UO; Sands M; Dong Y
    Appl Radiat Isot; 2003 May; 58(5):567-73. PubMed ID: 12735973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: a preliminary animal study.
    Subramanian S; Das T; Chakraborty S; Sarma HD; Banerjee S; Samuel G; Venkatesh M
    Cancer Biother Radiopharm; 2010 Oct; 25(5):539-43. PubMed ID: 20849309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of intrahepatic I-131 ethiodol on a patient with hepatocellular carcinoma. Therapeutic feasibility study.
    Park CH; Suh JH; Yoo HS; Lee JT; Kim DI
    Clin Nucl Med; 1986 Jul; 11(7):514-7. PubMed ID: 3015472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer.
    Das T; Chakraborty S; Sarma HD; Venkatesh M; Banerjee S
    Nucl Med Commun; 2009 May; 30(5):362-7. PubMed ID: 19282794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed-ligand complexes of yttrium-90 dialkyldithiocarbamates with 1,10-phenanthroline as a possible agent for therapy of hepatocellular carcinoma.
    Lopez A; Noiret N; Garin E; Lepareur N
    Appl Radiat Isot; 2014 Dec; 94():241-246. PubMed ID: 25238135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry of iodine-131 ethiodol in the treatment of hepatoma.
    Madsen MT; Park CH; Thakur ML
    J Nucl Med; 1988 Jun; 29(6):1038-44. PubMed ID: 2836572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc.
    Liu CB; Liu GZ; Liu N; Zhang YM; He J; Rusckowski M; Hnatowich DJ
    Nucl Med Biol; 2003 Feb; 30(2):207-14. PubMed ID: 12623121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic artery injection of Yttrium-90-lipiodol: biodistribution in rats with hepatoma.
    Wang SJ; Lin WY; Lui WY; Chen MN; Tsai ZT; Ting G
    J Nucl Med; 1996 Feb; 37(2):332-5. PubMed ID: 8667072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuning the lipophilic nature of pyclen-based 90Y3+ radiopharmaceuticals for β-radiotherapy.
    Le Fur M; Fougère O; Lepareur N; Rousseaux O; Tripier R; Beyler M
    Metallomics; 2021 Dec; 13(12):. PubMed ID: 34850060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma.
    Rhee TK; Omary RA; Gates V; Mounajjed T; Larson AC; Barakat O; Sato KT; Mulcahy M; Gordon S; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2005 Aug; 16(8):1085-91. PubMed ID: 16105920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and biodistribution of yttrium-90 Lipiodol in rats following hepatic arterial injection.
    Wang SJ; Lin WY; Chen MN; Shen LH; Tsai ZT; Ting G
    Eur J Nucl Med; 1995 Mar; 22(3):233-6. PubMed ID: 7789396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 90Y-microspheres on liver tumors: comparison of intratumoral injection method and intra-arterial injection method.
    Lin WY; Tsai SC; Hsieh JF; Wang SJ
    J Nucl Med; 2000 Nov; 41(11):1892-7. PubMed ID: 11079501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted transarterial therapy of Vx-2 rabbit liver tumor with Yttrium-90 labeled ferromagnetic particles using an external magnetic field.
    Kobeiter H; Georgiades CS; Leakakos T; Torbenson M; Hong K; Geschwind JF
    Anticancer Res; 2007; 27(2):755-60. PubMed ID: 17465199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates.
    Gansow OA
    Int J Rad Appl Instrum B; 1991; 18(4):369-81. PubMed ID: 1864725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regressive DOTA labelling performance with indium-111 and yttrium-90 over a week of use.
    Hainsworth JE; Mather SJ
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1348. PubMed ID: 16142470
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents.
    Ohishi H; Uchida H; Yoshimura H; Ohue S; Ueda J; Katsuragi M; Matsuo N; Hosogi Y
    Radiology; 1985 Jan; 154(1):25-9. PubMed ID: 2981114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yttrium-90 microspheres (TheraSphere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma.
    Allison C
    Issues Emerg Health Technol; 2007 Sep; (102):1-6. PubMed ID: 17824141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
    Giblin MF; Sieckman GL; Shelton TD; Hoffman TJ; Forte LR; Volkert WA
    Nucl Med Biol; 2006 May; 33(4):481-8. PubMed ID: 16720239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and biodistribution of rhenium-188 ECD/Lipiodol in rats following hepatic arterial injection.
    Luo TY; Hsieh BT; Wang SJ; Lin WY; Lee TW; Shen LH; Su MJ
    Nucl Med Biol; 2004 Jul; 31(5):671-7. PubMed ID: 15219287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The Royal Spanish Pharmacopoeia: labeling platelets with (111)indium-oxine].
    Freire JM
    Rev Esp Med Nucl; 2000 Jun; 19(3):254-5. PubMed ID: 11062093
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.